Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function

The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of clinical investigation 1993-04, Vol.91 (4), p.1656-1664
Hauptverfasser: HOLLERAN, W. M, TAKAGI, Y, MENON, G. K, LEGLER, G, FEINGOLD, K. R, ELIAS, P. M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1664
container_issue 4
container_start_page 1656
container_title The Journal of clinical investigation
container_volume 91
creator HOLLERAN, W. M
TAKAGI, Y
MENON, G. K
LEGLER, G
FEINGOLD, K. R
ELIAS, P. M
description The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function.
doi_str_mv 10.1172/jci116374
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288144</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8473508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-877485f858a837dc72cd8f2850a95d8ad6d51d293139eb7808ad0ee1b5f357aa3</originalsourceid><addsrcrecordid>eNpVUMtq3DAUFaUhmSZd9AMCWnSThRs9ozuLLMrQtCmBdpGszbUeUwXbciS7MH8fhRmGdnXgvO7lEPKJsy-cG3H9bCPnN9Kod2TFtYYGhIT3ZMWY4M3aSDgjH0p5ZowrpdUpOQVlpGawIuV3TtaXEsctTYH6KTqfB-zptl9sKrve-oxDJQuNhWb_ssTsHQ0p0zTN8c054FAh4kjtMuPo01LoVEs8drGP8452mHP0mYZltHNM4wU5CdgX__GA5-Tp7tvj5kfz8Ov7_ebrQ2M1U3MDxijQATQgSOOsEdZBEKAZrrUDdDdOcyfWksu17wywSjHveaeD1AZRnpPbfe-0dIN31o9zxr6dcn0779qEsf1fGeOfdpv-tgKgDlXzV_u8zamU7MMxyln7tnv7c3O_3716L_-9dXQehq7654OOxWIfMo42lqNNGaGFYvIVdoWPCw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>HOLLERAN, W. M ; TAKAGI, Y ; MENON, G. K ; LEGLER, G ; FEINGOLD, K. R ; ELIAS, P. M</creator><creatorcontrib>HOLLERAN, W. M ; TAKAGI, Y ; MENON, G. K ; LEGLER, G ; FEINGOLD, K. R ; ELIAS, P. M</creatorcontrib><description>The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function.</description><identifier>ISSN: 0021-9738</identifier><identifier>EISSN: 1558-8238</identifier><identifier>DOI: 10.1172/jci116374</identifier><identifier>PMID: 8473508</identifier><identifier>CODEN: JCINAO</identifier><language>eng</language><publisher>Ann Arbor, MI: American Society for Clinical Investigation</publisher><subject>Administration, Topical ; Animals ; Biological and medical sciences ; Cell Membrane Permeability ; Cyclohexenes ; Epidermis - chemistry ; Epidermis - cytology ; Epoxy Compounds - pharmacology ; Fundamental and applied biological sciences. Psychology ; Glucosidases - antagonists &amp; inhibitors ; Glucosylceramides - pharmacokinetics ; Inositol - analogs &amp; derivatives ; Inositol - pharmacology ; Male ; Mice ; Mice, Hairless ; Skin - chemistry ; Skin - cytology ; Sphingolipids - analysis ; Sphingolipids - pharmacokinetics ; Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</subject><ispartof>The Journal of clinical investigation, 1993-04, Vol.91 (4), p.1656-1664</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c504t-877485f858a837dc72cd8f2850a95d8ad6d51d293139eb7808ad0ee1b5f357aa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288144/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC288144/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4725240$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8473508$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HOLLERAN, W. M</creatorcontrib><creatorcontrib>TAKAGI, Y</creatorcontrib><creatorcontrib>MENON, G. K</creatorcontrib><creatorcontrib>LEGLER, G</creatorcontrib><creatorcontrib>FEINGOLD, K. R</creatorcontrib><creatorcontrib>ELIAS, P. M</creatorcontrib><title>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function.</description><subject>Administration, Topical</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cell Membrane Permeability</subject><subject>Cyclohexenes</subject><subject>Epidermis - chemistry</subject><subject>Epidermis - cytology</subject><subject>Epoxy Compounds - pharmacology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glucosidases - antagonists &amp; inhibitors</subject><subject>Glucosylceramides - pharmacokinetics</subject><subject>Inositol - analogs &amp; derivatives</subject><subject>Inositol - pharmacology</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Hairless</subject><subject>Skin - chemistry</subject><subject>Skin - cytology</subject><subject>Sphingolipids - analysis</subject><subject>Sphingolipids - pharmacokinetics</subject><subject>Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</subject><issn>0021-9738</issn><issn>1558-8238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUMtq3DAUFaUhmSZd9AMCWnSThRs9ozuLLMrQtCmBdpGszbUeUwXbciS7MH8fhRmGdnXgvO7lEPKJsy-cG3H9bCPnN9Kod2TFtYYGhIT3ZMWY4M3aSDgjH0p5ZowrpdUpOQVlpGawIuV3TtaXEsctTYH6KTqfB-zptl9sKrve-oxDJQuNhWb_ssTsHQ0p0zTN8c054FAh4kjtMuPo01LoVEs8drGP8452mHP0mYZltHNM4wU5CdgX__GA5-Tp7tvj5kfz8Ov7_ebrQ2M1U3MDxijQATQgSOOsEdZBEKAZrrUDdDdOcyfWksu17wywSjHveaeD1AZRnpPbfe-0dIN31o9zxr6dcn0779qEsf1fGeOfdpv-tgKgDlXzV_u8zamU7MMxyln7tnv7c3O_3716L_-9dXQehq7654OOxWIfMo42lqNNGaGFYvIVdoWPCw</recordid><startdate>19930401</startdate><enddate>19930401</enddate><creator>HOLLERAN, W. M</creator><creator>TAKAGI, Y</creator><creator>MENON, G. K</creator><creator>LEGLER, G</creator><creator>FEINGOLD, K. R</creator><creator>ELIAS, P. M</creator><general>American Society for Clinical Investigation</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>19930401</creationdate><title>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</title><author>HOLLERAN, W. M ; TAKAGI, Y ; MENON, G. K ; LEGLER, G ; FEINGOLD, K. R ; ELIAS, P. M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-877485f858a837dc72cd8f2850a95d8ad6d51d293139eb7808ad0ee1b5f357aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Administration, Topical</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cell Membrane Permeability</topic><topic>Cyclohexenes</topic><topic>Epidermis - chemistry</topic><topic>Epidermis - cytology</topic><topic>Epoxy Compounds - pharmacology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glucosidases - antagonists &amp; inhibitors</topic><topic>Glucosylceramides - pharmacokinetics</topic><topic>Inositol - analogs &amp; derivatives</topic><topic>Inositol - pharmacology</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Hairless</topic><topic>Skin - chemistry</topic><topic>Skin - cytology</topic><topic>Sphingolipids - analysis</topic><topic>Sphingolipids - pharmacokinetics</topic><topic>Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HOLLERAN, W. M</creatorcontrib><creatorcontrib>TAKAGI, Y</creatorcontrib><creatorcontrib>MENON, G. K</creatorcontrib><creatorcontrib>LEGLER, G</creatorcontrib><creatorcontrib>FEINGOLD, K. R</creatorcontrib><creatorcontrib>ELIAS, P. M</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HOLLERAN, W. M</au><au>TAKAGI, Y</au><au>MENON, G. K</au><au>LEGLER, G</au><au>FEINGOLD, K. R</au><au>ELIAS, P. M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1993-04-01</date><risdate>1993</risdate><volume>91</volume><issue>4</issue><spage>1656</spage><epage>1664</epage><pages>1656-1664</pages><issn>0021-9738</issn><eissn>1558-8238</eissn><coden>JCINAO</coden><abstract>The interstices of the mammalian stratum corneum contain lipids in a system of continuous membrane bilayers critical for the epidermal permeability barrier. During the transition from inner to outer stratum corneum, the content of polar lipids including glucosylceramides, decreases while ceramide content increases. We investigated whether inhibition of glucosylceramide hydrolysis would alter epidermal permeability barrier function. Daily topical applications of bromoconduritol B epoxide (BrCBE) to intact murine skin selectively inhibited beta-glucocerebrosidase, increased glucosylceramide content of stratum corneum with ceramide content remaining largely unchanged, and caused a progressive, reversible decrease in barrier function. Histochemistry of inhibitor-treated epidermis revealed persistence of periodic acid-Schiff-positive staining in stratum corneum cell membranes, consistent with retention of hexose moieties. Electron microscopy of inhibitor-treated samples revealed no evidence of toxicity or changes in the epidermal lipid delivery system. However, immature membrane structures persisted in the intercellular spaces throughout the stratum corneum, with reappearance of mature membrane structures progressing outward from the lower stratum corneum upon termination of BrCBE. Finally, the induced barrier abnormality was not reversed by coapplications of ceramide. These data demonstrate that glucosylceramide hydrolysis is important in the formation of the epidermal permeability barrier, and suggest that accumulation of glucosylceramides in stratum corneum intercellular membrane domains leads to abnormal barrier function.</abstract><cop>Ann Arbor, MI</cop><pub>American Society for Clinical Investigation</pub><pmid>8473508</pmid><doi>10.1172/jci116374</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9738
ispartof The Journal of clinical investigation, 1993-04, Vol.91 (4), p.1656-1664
issn 0021-9738
1558-8238
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_288144
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Administration, Topical
Animals
Biological and medical sciences
Cell Membrane Permeability
Cyclohexenes
Epidermis - chemistry
Epidermis - cytology
Epoxy Compounds - pharmacology
Fundamental and applied biological sciences. Psychology
Glucosidases - antagonists & inhibitors
Glucosylceramides - pharmacokinetics
Inositol - analogs & derivatives
Inositol - pharmacology
Male
Mice
Mice, Hairless
Skin - chemistry
Skin - cytology
Sphingolipids - analysis
Sphingolipids - pharmacokinetics
Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue
title Processing of epidermal glucosylceramides is required for optimal mammalian cutaneous permeability barrier function
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T07%3A09%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Processing%20of%20epidermal%20glucosylceramides%20is%20required%20for%20optimal%20mammalian%20cutaneous%20permeability%20barrier%20function&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=HOLLERAN,%20W.%20M&rft.date=1993-04-01&rft.volume=91&rft.issue=4&rft.spage=1656&rft.epage=1664&rft.pages=1656-1664&rft.issn=0021-9738&rft.eissn=1558-8238&rft.coden=JCINAO&rft_id=info:doi/10.1172/jci116374&rft_dat=%3Cpubmed_cross%3E8473508%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8473508&rfr_iscdi=true